Measuring coronary artery calcification (CAC) enables to optimize cardiovascular risk-stratification also in patients with type 2 diabetes mellitus (T2D), however the prevalence of CAC in randomly selected patients with T2D is uncertain. For this purpose we set out to examine and compare the occurrence of CAC in unselected T2D patients.
Introduction
Cardiovascular disease (CVD) and especially ischemic heart disease (IHD) are the most common complications and the principal causes of death in patients with type 2 Diabetes mellitus (T2D). Over 60% of people with T2D develop CVD, a more severe and costly complication than retinopathy 1 . The incidence of T2D is expected to increase rapidly during the following years and a concomitant rise in morbidity and mortality due to CVD, especially IHD is expected 2 . Therefore, it is important to consider how to intercept and treat individuals with T2D in the future. To reduce the risk of CVD, statin therapy should be considered for all patients with diabetes 3 .
However, it remains to be clarified whether patients can be stratified in subgroups who would benefit from a more aggressively preventive treatment algorithm, and who would do fine without. A tool for individualization of the risk of developing clinical symptoms of IHD would be preferable, since patients with diabetes often have blunted or atypical symptoms.
Coronary artery calcium (CAC) is a well-established marker for atherosclerosis, and measurement of CAC score predict future IHD, and all-cause mortality and provide a predictive power beyond standard risk factors in subjects without diabetes 4;5 . The presence of CAC in randomly selected patients with T2D is uncertain, but in selected patients the CAC score is elevated, and the score increases by the number of metabolic syndrome (MetS) risk factors 6 . Among patients with diabetes or MetS, the CAC score is correlated to a high annual rate of both CVD and IHD 7;8 . Indeed, CAC score measurements might optimize CVD risk stratification, and as a result, identify high risk subjects who could receive a more intensified risk modification regime, while in low risk subgroups a healthy lifestyle would be sufficient.
Consequently, the aim of this study was to assess the occurrence of CAC in unselected patients with T2D, and to identify a potential subgroup that might not benefit from intensified preventive medication.
Methods

Study Cohort
The 
Coronary artery calcification
A 64-slice non-contrast CT scan was performed as previously described 9 .
To quantify the CAC score, the Of the 54 participants with T2D, the Agatston score was missing in two due to inadequate scan quality (severe obesity) or claustrophobia, while of the 1157 healthy participants, the Agatston score was missing in four participants. Among patients with T2D the prevalence of men, 60 years old, smokers, hypertension and hypercholesterolemia were 50%, 58%, 33%, 69% and Total cholesterol (mmol/l) 4.5 ± 1.0 4.8 ± 1.1 5.5 ± 1.02 LDL-C (mmol/l) 2.4 ± 0.9 2.7 ± 0.9 3.3 ± 0.9 HDL-C (mmol/l) 1.4 ± 0.5 1.2 ± 0.4 1.5 ± 0.5 Triglycerides (mmol/l) 1.9 ± 1.1 2.5 ± 1.6 1. (Table 3) , while T2D was not. Excluding hypercholesterolemia from the multivariate regression, T2D continued to be without association to presence and extent of CAC (data not shown).
Discussion
We studied the prevalence of CAC in patients with T2D
and found that more than one third of these did not have coronary calcification. CAC was more frequent in T2D compared to subjects without diabetes, but T2D per se was not associated to CAC. These data may challenge the European recommendation that all patients with T2D
have an increased CVD risk, and should be treated accordingly 13 .
It is well known that patients with T2D are at increased risk of developing IHD, and several studies have demonstrated a two times higher CVD risk in patients with diabetes compared to those without 14;15 . These observations have lead to the conclusion, that asymptomatic patients with T2D have the same risk of myocardial infarction as patients with a prior myocardial infarction. Thus T2D has been proposed to be an IHD equivalent, and patients with diabetes should preferably receive intensive primary preventive therapy. Opposed to our study, one earlier study did also suggest that the CAC score in patients with T2D is similar to that of patients with established CVD 16 . However, these data were obtained from a selected population of patients with known diabetes for several years and consequently with a potential higher CAC score than patients with newly discovered diabetes. In our study both subjects with known and newly diagnosed T2D were enrolled, and we found a significantly higher CAC score in patients MetS as well as those with none of these conditions. The above is in concordance with our study; when adjusting for covariates in multivariate logistic regression, T2D 
Limitations
Only 69% of invited subjects accepted screening.
Therefore, it may be argued that our study does not represent a truly random population sample, since people who agree to participate may be selected and healthier than the general population. However, the participation rate in our study is high, when compared with earlier studies. 
